Phase 3b Trial of Fezolinetant Shows Positive Topline Results for Treatment of VMS Due to Menopause ...Middle East

Study evaluated 24-week efficacy and safety of Astellas' fezolinetant in women considered unsuitable for hormone therapy TOKYO, June 27, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced positive topline results from the...

Hence then, the article about phase 3b trial of fezolinetant shows positive topline results for treatment of vms due to menopause was published today ( Wednesday 28/06/2023 - 02:33 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Phase 3b Trial of Fezolinetant Shows Positive Topline Results for Treatment of VMS Due to Menopause )

Also on site :

• Seizure of Russian-flagged oil tanker: what we know so far
• Fatal I-55 crash shuts down lanes in southwest suburbs; ‘major' traffic backups expected
• Nestlé pulls baby milk batches amid safety fears